[{"orgOrder":0,"company":"SignPath Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Curcumin","moa":"PPAR gamma","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SignPath Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SignPath Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SignPath Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by SignPath Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Lipocurc has advantage of not only safely suppressing interleukin-6 by 83%, it also profoundly suppresses TNF-alpha by 77% and IL-1 beta by 85% as well as suppressing RANTES, IL-8, MCP-1& MIP-alpha.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 17, 2020

                          Lead Product(s) : Curcumin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank